COVID-19 and mortality in patients with systemic lupus erythematosus

  • Nancy Verónica Alva Arroyo Hospital Angeles Mocel (San Miguel Chapultepec, México)
  • Nancy Hernández-Sánchez Centro Médico ABC (Ciudad de México, México)
  • José Carlos Gasca-Aldama Hospital Star Médica Centro (Ciudad de México, México)
  • Ibzan Salvador-Ibarra Hospital Ángeles Mocel (San Miguel Chapultepec, México)
DOI: https://doi.org/10.36104/amc.2022.2551

Abstract

December 2019, a new disease caused by coronavirus 2019 (COVID19) has broken out in Wuhan, China. Causative of severe acute respiratory syndrome (SARS-CoV2)

Some cases associate COVID-19 and autoimmune disorders; the role of this virus in autoimmunity is poorly understood. Systemic lupus erythematosus (SLE) is an autoimmune disease. Baricitinib is a Janus kinase inhibitor (JAK) molecule approved for the treatment of autoimmune and inflammatory disorders, recently used for the management of severe COVID-19 disease.

These are 4 cases of SLE with COVID 19, two of which were admitted to the intensive care unit, died, with a history of lupus nephritis. The next two cases survived. The risk factors that increase mortality in SLE are still unknown, however, lupus nephritis was associated with mortality in COVID-19. More studies are required to understand the risk between autoimmune diseases and COVID-19.

Metrics

Metrics Loading ...
Published
2022-02-03
How to Cite
Alva Arroyo, N. V., Hernández-Sánchez, N., Gasca-Aldama, J. C., & Salvador-Ibarra, I. (2022). COVID-19 and mortality in patients with systemic lupus erythematosus. Acta Medica Colombiana, 47(4). https://doi.org/10.36104/amc.2022.2551
Issue
Vol. 47 No. 4 (2022): REVISTA ACTA MEDICA COLOMBIANA - DIGITAL
Section
Case Reports

Copyright (c) 2022 Nancy Alva Arroyo

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Acta Medica Colombiana uses the CC-BY 4.0 license. Authors retain all rights over their work.